Autoimmune Disorders Breakout, KI-Mayo Meeting 2022
Program Chairs and Moderators: Vanda Lennon (MC), Elisabet Svenugsson (KI), Vilija Oke (KI), Eoin Flanagan (MC), Veena Taneja, Lina Diaz (KI) and Helena Idborg (KI)
Please note that minor change in the agenda might occur.
Autoimmune Disorders Breakout Session
15:30- 17:30 PM (Stockholm); 8:30- 10:30 AM (Rochester) 6:30 -8.30 AM (Phoenix)
Welcome and Overview of Session Day One
- 15:30pm /8:30am/6:30am : Welcome History of Autoimmune Neurology, Vanda Lennon
- 15:55pm/8:55am/6:55: The incidence of myelin oligodendrocyte glycoprotein antibody-associated disease in Stockholm, Sweden - Katarina Fink (KI/MC)
- 16:05pm/9:05am/7:05am: Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3AR1 as drug targets in neuropsychiatric systemic lupus erythematosus, Julius Lindblom (KI)
- 16:15pm/9:15am/7:15am: Smoking and alcohol use are associated to the development of Myasthenia gravis, Malin Petersson (KI)
- 16:25pm/9:25am/7:25am: Sustained low relapse rate with highly variable B cell re-population dynamics with extended rituximab dosing intervals in multiple sclerosis, Chiara Stravaggi Cucuzza (KI)
- 16:35pm/9:35am/7:35am: Continued discussions/short break
- 16:50pm/9:50am/7:50am:Comorbidity Clusters Define Subgroups of Patients with Rheumatoid Arthritis who Exhibit Different Survival Prognosis, Cynthia S. Crowson (MC)
- 17:00pm/10:00am/8:00am: Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis, Bradly A. Kimbrough
- 17:10pm/10:10am/8:10am: Active rheumatoid arthritis and associated comorbidities increase risk of dementia: A population-based cohort study, Chanakya Kodishala (MC)
- 17:20pm/10:20am/8:20am: Increasing incidence of large artery manifestations in patients with giant cell arteritis, a population-based cohort over 70 years, Mahmut Kaymakci (MC)
- 17:30pm/10:30am/8:30am: Transition and break
- 17:45pm/10:45am/8:45am: Murdock Lecture
- 18:30pm/11:30am/9:30am: Keynote Lecture
16:00- 19:15 PM (Stockholm); 9:00- 11:15 AM (Rochester) 7:00 -10.15 AM (Phoenix)
Autoimmune Disorders Breakout Session
- 16:15pm/9:15am/7:15am: SLE research at KI, Elisabet Svenungsson (KI)
- 16:40pm/9:40am/7:40am: Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades, Ali Duarte (MC)
- 16:50pm/9:50am/7:50am: Drug repurposing for treating lupus nephritis based on transcriptome profiling and autoimmunity-related serological markers, Ioannis Parodis (KI/MC)
- 17:10pm/10:10am/8:10am: Medication adherence in patients with systemic lupus erythematosus: results from a Swedish survey study, Shahrzad Kia Komujuni (MC)
- 17:10pm/10:10am/8:10am: Continued discussions/ short break
- 17:25pm/10:25am/8:25am: Risk factors for recurrent thrombosis and cause of death in patients with antiphospholipid syndrome; a Swedish cohort study, Natali Karandyszowska (MC)
- 17:35pm/10:35am/8:35am: Extracellular vesicles as potential biomarkers of early disease stage in Systemic sclerosis, Jelena Colic (KI)
- 17:45pm/10:45am/8:45am: Mice expressing patient-derived TCRs show reactivity to citrullinated antigens in the context of HLA-DR4, Bruno Raposo (KI)
- 17:55pm/10:55am/8:55am: Immune responses and disease marker changes following SARS-CoV-2 mRNA vaccination in a cohort of rheumatic disease patients, Hu Zeng (MC)
- 18:05pm/11:05am/9:05am: Muscle T cell signatures and clonally expanded cytotoxic T cells are identified in idiopathic inflammatory myopathies using single-cell sequencing, Begum Horuluoglu (KI)
- 18:15pm/11:15am/9:15am: Transition and break
- 18:30pm/11:30am/9:30am: Key Note (30 min presentation & 15 min Q&A) (hybrid)